On War and Drugs

Like the thick smoky aftertaste that lingers after bonfire night merrymaking, memory hangs heavy in the air during the early weeks of November in the UK. As the oppressive darkness of the ironically named daylight-savings time settles in, we cast our collective memory back to the foiled attempt at Gunpowder Treason in 1605. More poignantly, … Continued

Strengthening the European Psychedelic Ecosystem: Partnership Between Octarine Bio and Clerkenwell Health

  The announcement of a partnership between Clerkenwell Health and Octarine Bio signals a momentous time for the growth and development of the European psychedelic ecosystem. This exciting partnership between these innovative startups aims to advance patient access to psychedelic treatments in Europe, and improve the quality of the psychedelic medicines produced in Europe.  Clerkenwell Health … Continued

The Overwhelming Argument for Rescheduling Psilocybin to Schedule 2 in the Misuse of Drugs Regulations 2001.

  In July, the Conservative Drug Policy Reform Group (‘CDPRG’) produced the most compelling argument (so far) for rescheduling of psilocybin.[1]  It is now time to: Assess the impact of that argument contained in the CDPRG’s report: “Medicinal use of psilocybin: Reducing restrictions on research and treatment” (the ‘Medicinal Use Report’); and Restate and emphasise … Continued

How COVID-19 will Affect the Psychedelic Renaissance

  Following the SARS virus outbreak in 2003, various studies detailed increased cases of depression and post-traumatic stress disorder. As the outbreak of the current COVID-19 pandemic, a coronavirus similar to SARS, continues to wreak havoc across the planet, an opinion piece in The Sacramento Bee suggests psychedelic therapy as a means to treat emotional … Continued